Status:

COMPLETED

Efficacy and Safety of a Dietary Supplement on Hair Growth and Hair Health in Female With Acute Telogen Effluvium

Lead Sponsor:

Activ'inside

Collaborating Sponsors:

Complife Italia Srl

Conditions:

Telogen Effluvium

Healthy

Eligibility:

FEMALE

18-52 years

Phase:

NA

Brief Summary

The study is aimed to assess the efficacy of a food supplement in reducing hair loss and accelerating the physiological growth in terms of elongation in female subjects showing acute telogen effluvium...

Eligibility Criteria

Inclusion

  • Good general health
  • Caucasian ethnicity
  • All hair type included
  • Transient acute telogen effluvium (duration less than 6 months) due to fatigue, seasonal change, deficiency of vitamins and minerals, stress, change or imbalance of normal daily routing, or emotional stress
  • Subjects having a positive pull test result
  • Subjects with minimum hair length of 6/7 cm
  • Subjects who stopped any anti hair loss treatment at least 3 months prior the study
  • Subjects agreeing not to take any treatment (oral or topic) able to interfere with the hair growth, diameter or fall during the whole study duration
  • Willingness not to dye/blench hair during the 2 weeks preceding each visit
  • Willingness not to cut hair for all the study length
  • Subjects registered with health social security or health social insurance
  • Subjects having signed their written Informed Consent form (ICF) and Privacy Policy for their participation in the study and a photograph authorization
  • Subjects able to understand the language used in the investigation centre and the information given
  • Subjects able to comply with the protocol and follow protocol constraints and specific requirements
  • Willingness to use during all the study period only the product to be tested
  • Willingness not to use similar products that could interfere with the product to be tested
  • Willingness to not vary the normal daily routine (i.e. lifestyle, physical activity, diet etc.)
  • Subjects under effective contraception (oral/not oral) if women of childbearing potential; not expected to be changed during the trial

Exclusion

  • Subjects who do not meet the inclusion criteria
  • Subject is taking part or planning to participate to another clinical study in the same or in another investigation centre
  • Subject who is deprived of freedom by administrative or legal decision or under guardianship
  • Subject admitted in a sanitary or social facilities
  • Subject who is planning a hospitalization during the study
  • Subjects under treatment with food supplements which could interfere with the functionality of the product under study
  • Subject has participated in another clinical study with anti-hair loss product or treatment within the last 24 weeks before the inclusion visit
  • Subject breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (if women of childbearing potential)
  • Subject has started or changed oestrogen-progesterone contraception or hormonal treatment, within the 3 months prior to the study or foreseeing it for the duration of the study
  • Subject having an acute, chronic or progressive illness liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
  • Subjects under radiotherapy, chemotherapy at any time
  • Subjects under locally pharmacological/non-pharmacological treatment applied on the area of interest monitored during the test
  • Subject having food disorders
  • Subject who has any other hair disorder or hair disease (female pattern hair loss, any type of alopecia…)
  • Subject having excessive and/or fluctuating hair shedding for more than 6 months
  • History or clinical signs of hyperandrogenaemia
  • Systemic treatment affecting the hair growth taken for more than 4 consecutive weeks during the last 24 weeks before inclusion visit
  • Systemic or local androgenetic alopecia treatment or product, taken or applied (Minoxidil, Aminexil, Finasteride, Dutasteride, cosmetic solution or capsules with vitamin B, zinc, caffeine…) for more than 4 consecutive weeks during the last 24 weeks before the inclusion visit
  • Any hair care product applied on the scalp between the last shampoo and the inclusion visit (e.g. gel, hairspray, wax, foam…)
  • Scalp surgery (hair transplants, laser) at any time.
  • Not menopausal women

Key Trial Info

Start Date :

September 30 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 24 2025

Estimated Enrollment :

66 Patients enrolled

Trial Details

Trial ID

NCT06545552

Start Date

September 30 2024

End Date

January 24 2025

Last Update

June 5 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Complife Italia srl

San Martino Siccomario, Italy, 27028